Skip Main Links
Prescribing InformationMedication Guide
Important Safety Information
For Healthcare
Providers
Unlock more
support
XYWAV® Narcolepsy Homepage

What is XYWAV

XYWAV is the first and only low‑sodium* oxybate treatment for cataplexy and/or excessive daytime sleepiness (EDS) in narcolepsy

*XYWAV contains 131 mg of sodium at the maximum recommended nightly dose.

Person working with elephant (made of salt) in the room

XYWAV, taken at night, is thought to work during sleep to help improve 2 common symptoms of narcolepsy during the day

XYWAV is the first and only low-sodium oxybate approved by the FDA for treating cataplexy and/or EDS in people ages 7 years and older with narcolepsy.

XYWAV can be taken in addition to daytime medications like stimulants. Be sure to talk to your doctor about any medications you are taking or plan to take.

  • The exact way XYWAV works for the treatment of cataplexy and EDS in patients with narcolepsy is unknown.
Learn more

Reasons to talk to your doctor about XYWAV today

XYWAV is thought to work during sleep to help improve symptoms of cataplexy and EDS during the day.

  • The exact way XYWAV works for the treatment of cataplexy and EDS in patients with narcolepsy is unknown.

XYWAV is a low-sodium oxybate treatment with 92% less sodium than high-sodium oxybates. That's as much as ~1509 mg less sodium per night.§

  • §At the maximum recommended nightly dose.

Choosing XYWAV over high-sodium oxybates, means you can help treat your symptoms of cataplexy and/or EDS in narcolepsy while also reducing your sodium intake, a modifiable risk factor for cardiovascular disease.

XYWAV is the first and only lower-sodium oxybate approved by the FDA for treating cataplexy and/or excessive daytime sleepiness (EDS) in people ages 7 years and older with narcolepsy.

Compared to XYREM® (sodium oxybate) oral solution and LUMRYZ (sodium oxybate) for extended-release oral suspension. XYWAV has never been directly compared to XYREM or LUMRYZ in a clinical study.

Get the Discussion Guide

When I learned about the low sodium content of XYWAV, I was immediately interested.”

Brooke

Diagnosed with narcolepsy type 1.

watch brooke's story

Compensated for her time. Results may vary.

How was XYWAV studied?

The efficacy and safety of XYWAV was studied in 201 adults with narcolepsy with cataplexy who had at least 14 cataplexy attacks in a typical 2‑week period before they took any treatment.¶#

All people in the clinical study started treatment with XYWAV.

The majority of participants (59%) continued taking their stimulant or wake‑promoting agent along with XYWAV.

XYWAV was adjusted to a stable dose (the dose that worked best for each person). Then they were randomly assigned to:

  • Continue treatment with XYWAVOR
  • Stop taking XYWAV for 2 weeks. These people were switched to a placebo, a treatment that is inactive. This was to see if there was a difference in their symptoms
Study design chart showing clinical study timeline, and how participants were randomized to take placebo or XYWAV before measuring symptoms.Study design chart showing clinical study timeline, and how participants were randomized to take placebo or XYWAV before measuring symptoms.Study design chart showing clinical study timeline, and how participants were randomized to take placebo or XYWAV before measuring symptoms.
  • Study included people aged 18-70.
  • #Not everyone completed each part of the trial. Of the 201 patients, 134 were included in the 2-week period that measured how well XYWAV worked.
ASK ABOUT XYWAV

Unlike other medications taken during the day, XYWAV is taken at night

Get valuable information about XYWAV from experts in sleep medicine

Learn about narcolepsy and also XYWAV, which may help treat cataplexy and/or EDS in people with narcolepsy. Plus, learn about the sodium content of XYWAV and why that matters for people with narcolepsy.

Intro to Xywav

XYWAV® (calcium, magnesium, potassium, and sodium oxybates) oral solution, 0.5 g/mL total salts (equivalent to 0.413 g/mL of oxybate) is a prescription medicine used to treat:

  • the following symptoms in people 7 years of age or older with narcolepsy:
    • sudden onset of weak or paralyzed muscles (cataplexy)
    • excessive daytime sleepiness (EDS)
  • idiopathic hypersomnia (IH) in adults.

Important Safety Information

WARNING: Taking XYWAV with other central nervous system (CNS) depressants such as medicines used to make you or your child fall asleep, including opioid analgesics, benzodiazepines, sedating antidepressants, antipsychotics, sedating anti-epileptic medicines, general anesthetics, muscle relaxants, alcohol, or street drugs, may cause serious medical problems, including trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), fainting (syncope), and death.

The active ingredient of XYWAV is a form of gamma-hydroxybutyrate (GHB). Abuse or misuse of illegal GHB alone or with other drugs that cause changes in alertness (or consciousness) has caused serious side effects. These effects include seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma, and death. Call your doctor right away if you or your child has any of these serious side effects.

Because of these risks, you have to go through the XYWAV and XYREM REMS to have your or your child's prescription for XYWAV filled.

Do not take XYWAV if you take or your child takes other sleep medicines or sedatives (medicines that cause sleepiness), drinks alcohol, or has a rare problem called succinic semialdehyde dehydrogenase deficiency.

Keep XYWAV in a safe place to prevent abuse and misuse. Selling or giving away XYWAV may harm others, and is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Anyone who takes XYWAV should not do anything that requires them to be fully awake or is dangerous, including driving a car, using heavy machinery, or flying an airplane, for at least 6 hours after taking XYWAV. Those activities should not be done until you know how XYWAV affects you or your child.

XYWAV can cause serious side effects, including the following:

  • Breathing problems, including slower breathing, trouble breathing, and/or short periods of not breathing while sleeping (sleep apnea). People who already have breathing or lung problems have a higher chance of having breathing problems when they use XYWAV.
  • Mental health problems, including confusion, seeing or hearing things that are not real (hallucinations), unusual or disturbing thoughts (abnormal thinking), feeling anxious or upset, depression, thoughts of killing yourself or trying to kill yourself, increased tiredness, feelings of guilt or worthlessness, or difficulty concentrating. Tell your doctor if you or your child have or had depression or have tried to harm yourself or themselves. Call your doctor right away if you have or your child has symptoms of mental health problems or a change in weight or appetite.
  • Sleepwalking. XYWAV can cause sleepwalking, which can cause injuries. Call your doctor if this occurs.

The most common side effects of XYWAV in adults include nausea, headache, dizziness, anxiety, insomnia, decreased appetite, excessive sweating (hyperhidrosis), vomiting, diarrhea, dry mouth, parasomnia (a sleep disorder that can include abnormal dreams, abnormal rapid eye movement (REM) sleep, sleep paralysis, sleep talking, sleep terror, sleep-related eating disorder, sleepwalking, and other abnormal sleep-related events), somnolence, fatigue, and tremor.

The most common side effects of XYREM (which also contains oxybate like XYWAV) in children include nausea, bedwetting, vomiting, headache, weight decrease, decreased appetite, dizziness, and sleepwalking.

XYWAV can cause physical dependence and craving for the medicine when it is not taken as directed. These are not all the possible side effects of XYWAV.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information, including BOXED Warning, and Medication Guide.

Up Arrow Icon
Jazz Pharmaceuticals homepage
Unlock more support

This site is intended for US residents only.

© 2023 Jazz Pharmaceuticals plc or its subsidiaries US-XYW-2200245 Rev1123